Contract Manufacturing, Drug Substance, API

Cascade Chemistry Expands API Manufacturing Capacity

February 18, 2021

Cascade began production on new facilities to manufacture APIs for clinical and commercial GMP production.

Quotient Sciences Acquires CDMO Arcinova

February 17, 2021

The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.

Piramal Expands API Capacity in Michigan

December 09, 2020

Piramal Pharma Solutions invests in expanded potent and non-potent API development and manufacturing at its Riverview, MI facility.

Cambrex to Invest More than $50 Million into Iowa Site Expansion

November 18, 2020

The expansion will be designed to meet the growing demand for small molecule drug substance development and manufacturing.

CordenPharma Adds Highly Potent API Laboratory to its Colorado Facility

October 19, 2020

The lab, which is currently available to customers, can handle highly potent compounds.

A Great Manipulation: The Value of Engineering Particle Properties

August 03, 2020

Particle engineering is a useful tool to manipulate API particles into a form that is manufacturable and deliverable to the patient.

CordenPharma Expands Lipid Supply for Moderna

June 04, 2020

CordenPharma announces expansion of lipid excipients supply for coronavirus vaccine scale up.

Novavax Contracts to Expand Adjuvant Production

June 04, 2020

Agreements with the PolyPeptide Group and AGC Biologics will scale up production of the Novavax Matrix-M adjuvant.

BARDA Funds US-based Drug Manufacturing Initiative

May 19, 2020

HHS announces $354 million in funding for private industry to manufacture generic drugs in the US from raw materials to finished product.

Evonik Expands Capacity in Germany

May 06, 2020

CMO Evonik begins capacity expansion of APIs and intermediates at its sites in Dossenheim and Hanau Germany to increase EU supply security for drug products.